Japan · Delayed Price · Currency is JPY Eisai Company Description
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan.
The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aβ) protofibrils; and Dayvigo, a novel small molecule compound.
The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas.
It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally.
The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955.
Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1941 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10,543 |
| CEO | Haruo Naito |
Contact Details
Address: 4-6-10 Koishikawa Tokyo, 112-8088 Japan | |
| Phone | 81 3 3817 3700 |
| Website | eisai.co.jp |
Stock Details
| Ticker Symbol | 4523 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3160400002 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Haruo Naito | Chief Executive Officer |
| Takuya Oyama | Chief Financial Officer |
| Keisuke Naito | Chief Operating Officer |
| Takuya Oyama | Head of Investor Relations |